<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Eupraxia Pharmaceuticals Inc — News on 6ix</title>
    <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc</link>
    <description>Latest news and press releases for Eupraxia Pharmaceuticals Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 22 Apr 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/eupraxia-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <item>
      <title>Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-to-present-at-digestive-disease-week-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-to-present-at-digestive-disease-week-annual-meeting</guid>
      <pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
      <description>VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (&quot;E...</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis&amp;#xA0;</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-reports-positive-nine-month-tissue-health-and-symptom-data-from-the-highest-dose-cohort-in-its-ongoing-phase-1b2a-resolve-trial-in-eosinophilic-esophagitisandxa0</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-reports-positive-nine-month-tissue-health-and-symptom-data-from-the-highest-dose-cohort-in-its-ongoing-phase-1b2a-resolve-trial-in-eosinophilic-esophagitisandxa0</guid>
      <pubDate>Tue, 21 Apr 2026 11:00:00 GMT</pubDate>
      <description>This is the first release of 36-week symptom response &amp;amp; tissue health data for the highest do...</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-to-present-at-upcoming-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-to-present-at-upcoming-investor-conferences</guid>
      <pubDate>Mon, 13 Apr 2026 12:00:00 GMT</pubDate>
      <description>VICTORIA, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (&quot;Eu...</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-reports-six-month-symptom-data-from-the-highest-dose-cohort-in-its-ongoing-phase-1b2a-resolve-trial-in-eosinophilic-esophagitis</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-reports-six-month-symptom-data-from-the-highest-dose-cohort-in-its-ongoing-phase-1b2a-resolve-trial-in-eosinophilic-esophagitis</guid>
      <pubDate>Tue, 17 Mar 2026 11:00:00 GMT</pubDate>
      <description>For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose ...</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-reports-fourth-quarter-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-reports-fourth-quarter-2025-financial-results</guid>
      <pubDate>Fri, 13 Mar 2026 01:03:00 GMT</pubDate>
      <description>VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2025. All dollar values are in U.S. dollars unless stated otherwise. “2025 was a pivotal year for</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-closing-of-usdollar632-million-public-offering-including-full-exercise-of-underwriter-option-1</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-closing-of-usdollar632-million-public-offering-including-full-exercise-of-underwriter-option-1</guid>
      <pubDate>Fri, 20 Feb 2026 20:10:55 GMT</pubDate>
      <description>VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (&amp;#x2...</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering  Including Full Exercise of Underwriter Option</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-closing-of-usdollar632-million-public-offering-including-full-exercise-of-underwriter-option</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-closing-of-usdollar632-million-public-offering-including-full-exercise-of-underwriter-option</guid>
      <pubDate>Fri, 20 Feb 2026 20:10:00 GMT</pubDate>
      <description>VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the &quot;Offering&quot;) of 7,607,145 common shares of the Company (the “Common S</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-pricing-of-usdollar55-million-public-offering-of-common-shares-and-pre-funded-warrants</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-pricing-of-usdollar55-million-public-offering-of-common-shares-and-pre-funded-warrants</guid>
      <pubDate>Thu, 19 Feb 2026 07:18:00 GMT</pubDate>
      <description>VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the pricing of its previously announced public offering (the &quot;Offering&quot;) of 6,428,574 common shares of the Company (the “Common Shares&quot;) at a price</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Announces Proposed Public Offering</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-proposed-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-proposed-public-offering</guid>
      <pubDate>Wed, 18 Feb 2026 21:01:00 GMT</pubDate>
      <description>VICTORIA, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the Company has filed a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated February 5, 2024</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy&amp;#xA0;</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-reports-positive-tissue-health-data-from-its-ongoing-resolve-trial-in-eosinophilic-esophagitis-demonstrating-near-complete-improvement-on-biopsyandxa0</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-reports-positive-tissue-health-data-from-its-ongoing-resolve-trial-in-eosinophilic-esophagitis-demonstrating-near-complete-improvement-on-biopsyandxa0</guid>
      <pubDate>Thu, 08 Jan 2026 12:34:11 GMT</pubDate>
      <description>At week 12, the highest dosed patients achieved the best tissue response seen in the trial to dat...</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-reports-positive-tissue-123400384</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-reports-positive-tissue-123400384</guid>
      <pubDate>Thu, 08 Jan 2026 12:34:00 GMT</pubDate>
      <description>At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1.At lower doses, patients maintained the improvements in tissue health1 reported at week 12 out until week 36. Clinical remission2 was achieved by 8 weeks and maintained through 52 weeks in the majority of patients for which more than 60% of their esophagus was treated.EP-104GI continues to be well tolerated by patients receiving the drug; over 200</description>
    </item>
    <item>
      <title>Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/specific-biologics-welcomes-accomplished-biotechnology-leader-dr-richard-glickman-to-its-board-of-directors-2</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/specific-biologics-welcomes-accomplished-biotechnology-leader-dr-richard-glickman-to-its-board-of-directors-2</guid>
      <pubDate>Tue, 16 Dec 2025 15:00:00 GMT</pubDate>
      <description>Specific Biologics Inc. (&quot;Specific Biologics&quot;), a precision in vivo genome editing company developing highly predictable, efficient and specific Dualase® genome editors to treat the untreatable, today announced the appointment of Dr. Richard Glickman to its Board of Directors.</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-reports-additional-52-week-follow-up-data-from-the-resolve-trial-in-eosinophilic-esophagitis-eoe-demonstrating-consistent-results-after-dosing-with-ep-104gi</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-reports-additional-52-week-follow-up-data-from-the-resolve-trial-in-eosinophilic-esophagitis-eoe-demonstrating-consistent-results-after-dosing-with-ep-104gi</guid>
      <pubDate>Thu, 13 Nov 2025 22:00:00 GMT</pubDate>
      <description>The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durabili...</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-reports-third-quarter-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-reports-third-quarter-2025-financial-results</guid>
      <pubDate>Tue, 04 Nov 2025 21:39:26 GMT</pubDate>
      <description>Durable symptom and tissue responses observed out to 52 weeks following a single treatment with E...</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-positive-data-from-highest-dose-cohort-in-the-ongoing-resolve-trial-in-eosinophilic-esophagitis-and-plans-for-expansion-of-ep-104gi-development-programs</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-positive-data-from-highest-dose-cohort-in-the-ongoing-resolve-trial-in-eosinophilic-esophagitis-and-plans-for-expansion-of-ep-104gi-development-programs</guid>
      <pubDate>Mon, 29 Sep 2025 21:00:00 GMT</pubDate>
      <description>Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (C...</description>
    </item>
    <item>
      <title>Peterson Capital Hosts Canada Growth Conference in Ireland</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/peterson-capital-hosts-canada-growth-conference-in-ireland-2</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/peterson-capital-hosts-canada-growth-conference-in-ireland-2</guid>
      <pubDate>Thu, 25 Sep 2025 06:00:00 GMT</pubDate>
      <description>DUBLIN, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Seven of Canada&amp;#x2019;s fastest growing public compan...</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering&amp;#xA0;Including Full Exercise of Underwriter Option</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-closing-of-usdollar805-million-public-offeringandxa0including-full-exercise-of-underwriter-option</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-closing-of-usdollar805-million-public-offeringandxa0including-full-exercise-of-underwriter-option</guid>
      <pubDate>Wed, 24 Sep 2025 12:54:51 GMT</pubDate>
      <description>VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc.&amp;#xA0...</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-closing-us-125400039</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-closing-us-125400039</guid>
      <pubDate>Wed, 24 Sep 2025 12:54:00 GMT</pubDate>
      <description>VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the &quot;Offering&quot;) of 14,636,363 common shares of the Company (the “Common</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-pricing-of-usdollar70-million-public-offering-of-common-shares</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-pricing-of-usdollar70-million-public-offering-of-common-shares</guid>
      <pubDate>Tue, 23 Sep 2025 02:42:29 GMT</pubDate>
      <description>VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc.&amp;#xA0...</description>
    </item>
    <item>
      <title>Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares</title>
      <link>https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-proposed-public-offering-of-common-shares</link>
      <guid isPermaLink="true">https://6ix.com/company/eupraxia-pharmaceuticals-inc/news/eupraxia-pharmaceuticals-announces-proposed-public-offering-of-common-shares</guid>
      <pubDate>Mon, 22 Sep 2025 20:01:00 GMT</pubDate>
      <description>VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc.&amp;#xA0...</description>
    </item>
  </channel>
</rss>